用于治疗肝脏疾病的实验性细胞疗法中的新工具
New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.
作者信息
Ferrer Jennifer R, Chokechanachaisakul Attasit, Wertheim Jason A
机构信息
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Department of Chemistry, Northwestern University, Evanston, IL 60201, USA ; Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60201, USA ; International Institute for Nanotechnology, Northwestern University, Evanston, IL 60201, USA ; Simpson Querrey Institute for BioNanotechnology in Medicine, Northwestern University, Chicago, IL 60611, USA.
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, 676 St. Clair St. Suite 1900, Chicago, IL 60611, USA.
出版信息
Curr Transplant Rep. 2015 Jun 1;2(2):202-210. doi: 10.1007/s40472-015-0059-4.
The current standard of care for end stage liver disease is orthotopic liver transplantation (OLT). Through improvement in surgical techniques, immunosuppression, and general medical care, liver transplantation has become an effective treatment over the course of the last half-century. Unfortunately, due to the limited availability of donor organs, there is a finite limit to the number of patients who will benefit from this therapy. This review will discuss current research in experimental cellular therapies for acute, chronic, and metabolic liver failure that may be appropriate when liver transplantation is not an immediate option.
终末期肝病目前的标准治疗方法是原位肝移植（OLT）。在过去半个世纪里，通过手术技术、免疫抑制和普通医疗护理方面的改进，肝移植已成为一种有效的治疗方法。不幸的是，由于供体器官供应有限，能够从这种治疗中获益的患者数量存在着一个有限的上限。本综述将讨论针对急性、慢性和代谢性肝衰竭的实验性细胞疗法的当前研究，当肝移植并非即时选择时，这些疗法可能是合适的。
Zotero 插件